AI assistant
Evotec SE — Regulatory Filings 2012
Feb 16, 2012
151_rns_2012-02-16_4e03a343-f4e5-4746-af25-33584178ef21.html
Regulatory Filings
Open in viewerOpens in your device viewer
News Details
Corporate | 16 February 2012 07:26
Evotec and IR Pharma Establish Drug Discovery Alliance in the Field of Respiratory
Evotec AG / Key word(s): Alliance
16.02.2012 / 07:26
Hamburg, Germany - 16 February 2012: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX) and IR Pharma today announced that they have entered into an
exclusive strategic alliance to provide integrated drug discovery solutions
to Pharmaceutical and Biotech companies in the field of Respiratory
Diseases.
This alliance expands Evotec's already powerful drug discovery platform,
into the area of respiratory diseases through IR Pharma's world leading
expertise in in vitro and in vivo Respiratory pharmacology. As part of
this exclusive collaboration, Evotec is now positioned to offer seamless,
fully integrated respiratory and inflammation focused drug discovery
programmes to its partners, from target to nomination of pre-clinical
development candidates.
Dr Mario Polywka, Chief Operating Officer at Evotec AG, commented: 'We are
looking forward to partner with IR Pharma and are excited about the
potential of this alliance. IR Pharma has outstanding expertise in the
respiratory disease area including disease relevant in vivo models and
coupled with our world leading discovery engine and commercial reach, we
are sure we can bring outstanding value to existing and future partners and
collaborators in these demanding disease areas. This co-operation is a
significant addition to our strategy to offer the most comprehensive drug
discovery solutions to our partners. '
Prof Maria Belvisi, Director at IR Pharma Ltd, added: 'We are delighted to
join forces with Evotec and firmly believe that together, we will provide
efficient and innovative drug discovery solutions to our partners. We have
a range of highly validated models, focusing on Asthma, Cough and Chronic
Obstructive Pulmonary Disease (COPD), which ideally complement Evotec's
platform, thus enabling a fully integrated approach to drug discovery in
this challenging area.'
No financial details were disclosed.
Contact Evotec AG:
Dr Werner Lanthaler, Chief Executive Officer, Phone: +49.(0)40.56081-242,
[email protected]
End of Corporate News
16.02.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: [email protected]
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
156962 16.02.2012